美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

亚盛医药

41.04

+0.54131.34%

盘后：41.060.0200+0.05%16:10 EDT

成交量：2.07万

成交额：84.65万

市值：38.24亿

市盈率：-55.79

高：41.40

开：41.20

低：40.60

收：40.50

52周最高：48.45

52周最低：16.50

股本：9,316.78万

流通股本：7,158.28万

量比：1.70

换手率：0.03%

股息：- -

股息率：- -

每股收益(TTM):-0.7356

每股收益(LYR):-0.7356

净资产收益率：-159.65%

总资产收益率：-22.77%

市净率：40.89

市盈率(LYR):-55.79

数据加载中...

总览公司新闻公告

聚焦细胞凋亡三十载，亚盛医药迎“价值跃迁”

熬过寒冬，亚盛医药飚到300亿

21世纪商业评论

亚盛医药7月11日成交额为24.30万美元

亚盛医药拿下全球第二个Bcl-2抑制剂在国内与“全球首个”前后脚获批血液肿瘤适应证

每日经济新闻

今年医保目录调整工作方案公布；亚盛医药拿下全球第二个Bcl-2抑制剂 | 医药早参

每日经济新闻

亚盛医药：新药利沙托克拉获中国NMPA附条件批准上市

华尔街见闻

国产首个！亚盛医药Bcl-2抑制剂“利沙托克拉”获批上市

医药魔方Info

亚盛医药7月9日成交额为21.11万美元

亚盛医药（06855）任命Veet Misra博士为首席财务官任命黄智为全球企业发展&财务高级副总裁

亚盛医药7月7日成交额为25.50万美元

【港股生物医药板块震荡走强】港股生物医药板块震荡走强，康方生物、圣诺医药、歌礼制药涨超10%，亚盛医药涨超7%，复宏汉霖、科技药业、再鼎医药涨超4%。

亚盛医药7月2日成交额为22.13万美元

亚盛医药6月30日成交额为26.91万美元

亚盛医药6月26日成交额为57.36万美元

海通国际：维持亚盛医药-B(06855)“优于大市”评级目标价84.6港元

亚盛医药6月24日成交额为101.18万美元

亚盛医药6月23日成交额为33.44万美元

两家创新药企逆市大涨10%背后：创新药不炒BD了

亚盛医药上涨5.32%，报37.79美元/股，总市值32.92亿美元

亚盛医药点评：多项临床亮相ASCO和EHA大会，优秀数据助力管线商业化【东吴医药朱国广团队】

国广有话说

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/AAPG/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亚盛医药","latestPrice":41.04,"timestamp":1757361600000,"preClose":40.4987,"halted":0,"volume":20650,"hourTrading":{"tag":"盘后","latestPrice":41.06,"preClose":41.04,"latestTime":"16:10 EDT","volume":17,"amount":698.02,"timestamp":1757362205654},"delay":0,"floatShares":71582800,"shares":93167803,"eps":-0.735552,"marketStatus":"盘后交易","change":0.5413,"latestTime":"09-08 16:22:36 EDT","open":41.2,"high":41.4,"low":40.6,"amount":846476.6031,"amplitude":0.019754,"askPrice":41.2,"askSize":10000,"bidPrice":35.45,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.735552,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1757376000000},"marketStatusCode":4,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":40.4987,"postHourTrading":{"tag":"盘后","latestPrice":41.06,"preClose":41.04,"latestTime":"16:10 EDT","volume":17,"amount":698.02,"timestamp":1757362205654},"volumeRatio":1.704358},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":71582800,"roa":"-22.77%","roe":"-159.65%","lyrEps":-0.735552,"volumeRatio":1.704358,"shares":93167803,"dividePrice":0,"high":41.4,"amplitude":0.019754,"preClose":40.4987,"low":40.6,"week52Low":16.5,"pbRate":"40.89","psRate":"69.71","week52High":48.45,"institutionHeld":0,"latestPrice":41.04,"committee":-0.980198,"eps":-0.735552,"divideRate":0,"volume":20650,"delay":0,"ttmEps":-0.735552,"open":41.2,"prevYearClose":17.25,"prevWeekClose":40.4987,"prevMonthClose":42.47,"prevQuarterClose":39.375,"fiveDayClose":42.47,"twentyDayClose":41.95,"sixtyDayClose":29.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"AAPG","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"盘前","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1743652800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2025-09-05","current":-22.946281,"percent":0.993421,"low":-76.454813,"twenty":-59.664109,"median":-36.382297,"eighty":-31.979778,"high":-21.702816,"avg":-42.586735,"sd":14.167338,"marketCap":3724203040.4},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94},{"date":"2025-04-17","current":-29.520055,"twenty":-34.225935,"median":-32.760201,"eighty":-30.07059,"marketCap":1639709582.7},{"date":"2025-04-25","current":-41.553435,"twenty":-35.045268,"median":-32.920123,"eighty":-30.119556,"marketCap":2311372741.24},{"date":"2025-05-02","current":-38.492689,"twenty":-35.554336,"median":-33.187028,"eighty":-30.682879,"marketCap":2146245101.28},{"date":"2025-05-09","current":-37.35919,"twenty":-36.170996,"median":-33.361942,"eighty":-30.776099,"marketCap":2093177176.92},{"date":"2025-05-16","current":-35.007117,"twenty":-35.955639,"median":-33.43308,"eighty":-31.102567,"marketCap":1969122395.28},{"date":"2025-05-23","current":-39.338512,"twenty":-36.352488,"median":-33.608398,"eighty":-31.19472,"marketCap":2213435510.22},{"date":"2025-05-30","current":-38.856398,"twenty":-37.35919,"median":-33.992043,"eighty":-31.242401,"marketCap":2192363417.29},{"date":"2025-06-06","current":-42.814884,"twenty":-37.865895,"median":-34.141844,"eighty":-31.758144,"marketCap":2419987007.19},{"date":"2025-06-13","current":-48.171029,"twenty":-38.492689,"median":-34.477812,"eighty":-31.846105,"marketCap":2722575737.57},{"date":"2025-06-20","current":-55.929302,"twenty":-38.862859,"median":-34.635358,"eighty":-32.113451,"marketCap":3154688383.5},{"date":"2025-06-27","current":-59.787237,"twenty":-39.399619,"median":-35.123604,"eighty":-32.336589,"marketCap":3381751544.24},{"date":"2025-07-03","current":-64.068526,"twenty":-41.436089,"median":-35.258863,"eighty":-32.429915,"marketCap":3624015684.35},{"date":"2025-07-11","current":-59.084566,"twenty":-43.897892,"median":-35.501693,"eighty":-32.48435,"marketCap":3338745741.38},{"date":"2025-07-18","current":-61.880278,"twenty":-48.308604,"median":-35.791073,"eighty":-32.545465,"marketCap":3494679880.36},{"date":"2025-07-25","current":-58.315576,"twenty":-54.849764,"median":-35.921968,"eighty":-32.616809,"marketCap":3304687864.64},{"date":"2025-08-01","current":-60.559654,"twenty":-57.422661,"median":-36.233253,"eighty":-32.655768,"marketCap":3410643633.03},{"date":"2025-08-08","current":-69.260076,"twenty":-59.023969,"median":-36.597865,"eighty":-32.679287,"marketCap":3910472388.03},{"date":"2025-08-15","current":-72.346957,"twenty":-59.602544,"median":-37.391167,"eighty":-32.709995,"marketCap":4086922647.44},{"date":"2025-08-22","current":-26.724459,"twenty":-60.097702,"median":-37.493155,"eighty":-32.679287,"marketCap":4314209810.62},{"date":"2025-08-29","current":-24.396919,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"marketCap":3966417985.85},{"date":"2025-09-05","current":-22.946281,"twenty":-59.664109,"median":-36.382297,"eighty":-31.979778,"marketCap":3724203040.4}],"updateTime":1757362956878},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2551153924","title":"聚焦细胞凋亡三十载，亚盛医药迎“价值跃迁”","url":"https://stock-news.laohu8.com/highlight/detail?id=2551153924","media":"医曜","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551153924?lang=zh_cn&edition=fundamental","pubTime":"2025-07-14 08:25","pubTimestamp":1752452700,"startTime":"0","endTime":"0","summary":"千呼万唤始出来，亚盛医药的第二颗“重磅炸弹”利生妥终于落地。这背后的原因正是深耕细胞凋亡赛道二十载所引发的“进化”。利生妥则已经于2025年7月10日获批上市，成为中国首款自主研发、全球第二款Bcl-2抑制剂。作为这一靶点最早的布局者，亚盛医药靠“三十年，三款药”的坚持，用一次又一次的失败才最终看到了“胜利的大门”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714091629a4489865&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714091629a4489865&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ASPHF","AAPG","BK4139"],"gpt_icon":0},{"id":"2551941612","title":"熬过寒冬，亚盛医药飚到300亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2551941612","media":"21世纪商业评论","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551941612?lang=zh_cn&edition=fundamental","pubTime":"2025-07-13 19:13","pubTimestamp":1752405180,"startTime":"0","endTime":"0","summary":"同时，武田制药认购亚盛医药新发行7500万美元股份，成为第二大股东。今年初，亚盛医药在纳斯达克上市，成为首家实现先港股、后美股双重上市的生物医药企业。迄今，其股价已翻倍，过去两周，市值一度攀升至300亿港元。2009年，创始团队独立出来，成立亚盛医药。2023年，默沙东的研发经费是305.3亿美元，2024年全球十大药企中，有9家公司的研发经费超过100亿美元。2022年，国内药企研发经费总和超过1000亿元，不如默沙东一家。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250713191807a447c958&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250713191807a447c958&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG","06855"],"gpt_icon":0},{"id":"2550998338","title":"亚盛医药7月11日成交额为24.30万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550998338","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550998338?lang=zh_cn&edition=fundamental","pubTime":"2025-07-12 09:15","pubTimestamp":1752282914,"startTime":"0","endTime":"0","summary":"美东时间2025年7月11日，亚盛医药成交额为24.30万美元，成交额较昨日减少66.18%，当日成交量为6315.00股。亚盛医药于2025年7月11日跌6.14%，报38.24美元，该股过去5个交易日跌10.76%，年初至今涨121.68%，过去60日涨86.63%。公司专注于开发抑制蛋白质相互作用以恢复细胞凋亡或程序性细胞死亡的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712091523a445c7f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712091523a445c7f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2550098026","title":"亚盛医药拿下全球第二个Bcl-2抑制剂 在国内与“全球首个”前后脚获批血液肿瘤适应证","url":"https://stock-news.laohu8.com/highlight/detail?id=2550098026","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550098026?lang=zh_cn&edition=fundamental","pubTime":"2025-07-11 16:39","pubTimestamp":1752223174,"startTime":"0","endTime":"0","summary":"全球第二个Bcl-2抑制剂，来自中国。7月10日，亚盛医药发布公告，公司自研的新型Bcl-2选择性抑制剂“利生妥”（通用名：利沙托克拉）获附条件批准，可用于既往经过至少包含布鲁顿酪氨酸激酶（BTK）抑制剂在内的一种系统治疗的成人慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202507113454576954.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507113454576954.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2550674208","title":"今年医保目录调整工作方案公布；亚盛医药拿下全球第二个Bcl-2抑制剂 | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2550674208","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550674208?lang=zh_cn&edition=fundamental","pubTime":"2025-07-11 07:21","pubTimestamp":1752189698,"startTime":"0","endTime":"0","summary":"丨2025年7月11日星期五丨NO.1国家医保局公布2025年医保目录调整工作方案7月10日，国家医保局正式发布《2025年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整工作方案》《2025年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整申报指南》等文件。此前，今年将新增商保创新药目录一事曾备受关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202507113453786960.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507113453786960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK4139","BK1161","BK1574","AAPG","09939"],"gpt_icon":0},{"id":"2550617943","title":"亚盛医药：新药利沙托克拉获中国NMPA附条件批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2550617943","media":"华尔街见闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550617943?lang=zh_cn&edition=fundamental","pubTime":"2025-07-10 17:01","pubTimestamp":1752138081,"startTime":"0","endTime":"0","summary":"亚盛医药公告要点解读核心事件新药获批上市：公司自主研发的新型Bcl-2抑制剂利沙托克拉（利生妥）获中国NMPA附条件批准上市，成为中国首个上市用于治疗CLL/SLL的Bcl-2抑制剂，全球第二个上市的同类药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710170428a6a13e17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710170428a6a13e17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2550314611","title":"国产首个！亚盛医药Bcl-2抑制剂“利沙托克拉”获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2550314611","media":"医药魔方Info","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550314611?lang=zh_cn&edition=fundamental","pubTime":"2025-07-10 15:43","pubTimestamp":1752133404,"startTime":"0","endTime":"0","summary":"APG-2575是亚盛医药自主研发的新型口服Bcl-2选择性抑制剂，通过选择性抑制Bcl-2蛋白，恢复癌细胞的正常凋亡过程，从而达到治疗肿瘤的目的。Bcl-2抑制剂的出现让CLL/SLL的治疗有了进一步的革新。不过Bcl-2靶点成药性难度很高，靶点发现至今近40年，全球只有一款靶向Bcl-2的抑制剂获批上市，即艾伯维维奈克拉，此外，百济神州的索托克拉已申请上市，目前正在审评当中。力胜克拉的获批将为患者提供新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710155605a44207f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710155605a44207f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","ASPHF","06855","BK1161","AAPG"],"gpt_icon":0},{"id":"2550966716","title":"亚盛医药7月9日成交额为21.11万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550966716","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550966716?lang=zh_cn&edition=fundamental","pubTime":"2025-07-10 09:15","pubTimestamp":1752110115,"startTime":"0","endTime":"0","summary":"美东时间2025年7月9日，亚盛医药成交额为21.11万美元，成交额较昨日减少57.18%，当日成交量为5040.00股。亚盛医药于2025年7月9日涨1.26%，报41.87美元，该股过去5个交易日涨7.39%，年初至今涨142.72%，过去60日涨136.55%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-09|21.11万|-57.18%|5040.00|#|2025-07-08|49.29万|93.32%|1.19万|#|2025-07-07|25.50万|-73.46%|6072.00|#|2025-07-03|96.08万|334.10%|2.25万|#|2025-07-02|22.13万|1.03%|5607.00|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的新型小规模疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710091529a6a0632a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710091529a6a0632a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2549596497","title":"亚盛医药（06855）任命Veet Misra博士为首席财务官 任命黄智为全球企业发展&财务高级副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2549596497","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549596497?lang=zh_cn&edition=fundamental","pubTime":"2025-07-08 11:51","pubTimestamp":1751946699,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月8日，亚盛医药宣布，公司任命Veet Misra博士为首席财务官，并任命黄智先生为全球企业发展&财务高级副总裁。Misra博士和黄智先生均向公司董事长兼首席执行官杨大俊博士直接汇报。亚盛医药作为港股、纳斯达克双重主要上市的全球性创新药企业，正迈向新的历史发展阶段。亚盛医药首席财务官Veet Misra博士指出，加入亚盛医药担任首席财务官，我深感振奋。Misra博士拥有20多年的投资银行从业经验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","BK1161","AAPG","BK1574","BK4139"],"gpt_icon":0},{"id":"2549628415","title":"亚盛医药7月7日成交额为25.50万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549628415","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549628415?lang=zh_cn&edition=fundamental","pubTime":"2025-07-08 09:15","pubTimestamp":1751937314,"startTime":"0","endTime":"0","summary":"美东时间2025年7月7日，亚盛医药成交额为25.50万美元，成交额较昨日减少73.46%，当日成交量为6072.00股。亚盛医药于2025年7月7日跌1.89%，报42.04美元，该股过去5个交易日涨6.16%，年初至今涨143.71%，过去60日涨116.03%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-07|25.50万|-73.46%|6072.00|#|2025-07-03|96.08万|334.10%|2.25万|#|2025-07-02|22.13万|1.03%|5607.00|#|2025-07-01|21.91万|-18.59%|5597.00|#|2025-06-30|26.91万|1.80%|6844.00|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的新型小规模疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708091524a69bea2a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708091524a69bea2a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2548236822","title":"【港股生物医药板块震荡走强】港股生物医药板块震荡走强，康方生物、圣诺医药、歌礼制药涨超10%，亚盛医药涨超7%，复宏汉霖、科技药业、再鼎医药涨超4%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2548236822","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548236822?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 14:05","pubTimestamp":1751522751,"startTime":"0","endTime":"0","summary":"港股生物医药板块震荡走强，康方生物、圣诺医药、歌礼制药涨超10%，亚盛医药涨超7%，复宏汉霖、科技药业、再鼎医药涨超4%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/03140551458806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09926","LU0348783233.USD","HSCEI","LU1794554557.SGD","BK1588","BK4548","LU2488822045.USD","IE00B5MMRT66.SGD","LU1720050803.USD","BK4531","LU0417516571.SGD","BK1161","BK1191","BK4588","LU0348784397.USD","HSTECH","BK4585","ZLAB","02696","BK4139","01672","IE00B543WZ88.USD","01477","BK1515","IE00BPRC5H50.USD","09688","AAPG","BK1574","BK4614","BK4526","161726","07226","YANG","399441","02257"],"gpt_icon":0},{"id":"2548888842","title":"亚盛医药7月2日成交额为22.13万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548888842","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548888842?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 09:15","pubTimestamp":1751505314,"startTime":"0","endTime":"0","summary":"美东时间2025年7月2日，亚盛医药成交额为22.13万美元，成交额较昨日增加1.03%，当日成交量为5607.00股。亚盛医药于2025年7月2日涨2.21%，报39.85美元，该股过去5个交易日跌0.35%，年初至今涨131.01%，过去60日涨90.21%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-02|22.13万|1.03%|5607.00|#|2025-07-01|21.91万|-18.59%|5597.00|#|2025-06-30|26.91万|1.80%|6844.00|#|2025-06-27|26.43万|-53.92%|6734.00|#|2025-06-26|57.36万|-24.94%|1.45万|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的新型小规模疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703091529a4cc1fa6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703091529a4cc1fa6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2548004228","title":"亚盛医药6月30日成交额为26.91万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548004228","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548004228?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 09:15","pubTimestamp":1751332514,"startTime":"0","endTime":"0","summary":"美东时间2025年6月30日，亚盛医药成交额为26.91万美元，成交额较昨日增加1.80%，当日成交量为6844.00股。亚盛医药于2025年6月30日跌0.57%，报39.38美元，该股过去5个交易日涨5.99%，年初至今涨128.26%，过去60日涨71.2%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-06-30|26.91万|1.80%|6844.00|#|2025-06-27|26.43万|-53.92%|6734.00|#|2025-06-26|57.36万|-24.94%|1.45万|#|2025-06-25|76.41万|-24.48%|1.95万|#|2025-06-24|101.18万|202.59%|2.56万|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的新型小规模疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701091528a4c7ac9f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701091528a4c7ac9f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2546848765","title":"亚盛医药6月26日成交额为57.36万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546848765","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546848765?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 09:15","pubTimestamp":1750986914,"startTime":"0","endTime":"0","summary":"美东时间2025年6月26日，亚盛医药成交额为57.36万美元，成交额较昨日减少24.94%，当日成交量为1.45万股。亚盛医药于2025年6月26日涨2.05%，报40.81美元，该股过去5个交易日涨13.74%，年初至今涨136.58%，过去60日涨85.92%。公司专注于开发抑制蛋白质相互作用以恢复细胞凋亡或程序性细胞死亡的疗法。该公司的地理分部包括美国和中国大陆。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627091526a71fb179&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627091526a71fb179&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2546274392","title":"海通国际：维持亚盛医药-B(06855)“优于大市”评级 目标价84.6港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546274392","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546274392?lang=zh_cn&edition=fundamental","pubTime":"2025-06-26 10:56","pubTimestamp":1750906585,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海通国际发布研报称，结合亚盛医药-BASCO公布的数据，提高lisaftoclax在MDS适应症的研发成功率，及全球潜在销售峰值。基于WACC10.0%，永续增长率3.5%，对应目标价84.6HKD/股，维持“优于大市”评级。该行认为，该结果为后续开展该联合疗法用于此类患者的III期临床研究提供了有力的数据支持。该行认为数据初步展现了lisaftoclax在该适应症的疗效，有望填补相关难治领域临床的空白。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1309959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","AAPG"],"gpt_icon":0},{"id":"2546257054","title":"亚盛医药6月24日成交额为101.18万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546257054","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546257054?lang=zh_cn&edition=fundamental","pubTime":"2025-06-25 09:15","pubTimestamp":1750814115,"startTime":"0","endTime":"0","summary":"美东时间2025年6月24日，亚盛医药成交额为101.18万美元，成交额较昨日增加202.59%，当日成交量为2.56万股。亚盛医药于2025年6月24日涨6.86%，报39.7美元，该股过去5个交易日涨23.56%，年初至今涨130.14%，过去60日涨96.53%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-06-24|101.18万|202.59%|2.56万|#|2025-06-23|33.44万|-64.49%|9085.00|#|2025-06-20|94.16万|7.77%|2.52万|#|2025-06-18|87.38万|559.85%|2.47万|#|2025-06-17|13.24万|-30.22%|4195.00|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的新型小规模疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625091527a71c0fa7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625091527a71c0fa7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2545910424","title":"亚盛医药6月23日成交额为33.44万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545910424","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545910424?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 09:15","pubTimestamp":1750727714,"startTime":"0","endTime":"0","summary":"美东时间2025年6月23日，亚盛医药成交额为33.44万美元，成交额较昨日减少64.49%，当日成交量为9085.00股。亚盛医药于2025年6月23日跌0.62%，报37.15美元，该股过去5个交易日涨17.9%，年初至今涨115.36%，过去60日涨102.23%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-06-23|33.44万|-64.49%|9085.00|#|2025-06-20|94.16万|7.77%|2.52万|#|2025-06-18|87.38万|559.85%|2.47万|#|2025-06-17|13.24万|-30.22%|4195.00|#|2025-06-16|18.98万|111.17%|5911.00|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的新型小规模疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624091523a71a3e57&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624091523a71a3e57&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2545423100","title":"两家创新药企逆市大涨10%背后：创新药不炒BD了","url":"https://stock-news.laohu8.com/highlight/detail?id=2545423100","media":"谈思生物","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545423100?lang=zh_cn&edition=fundamental","pubTime":"2025-06-21 15:01","pubTimestamp":1750489264,"startTime":"0","endTime":"0","summary":"2025.06.21本文字数：2900，阅读时长大约7.25分钟导读：自6月17日港股创新药板块回调之际，亚盛医药和科济药业逆势大涨，分别凭借明星产品耐立克、APG-2575及CAR-T疗法CT071等的突出进展，吸引市场高度关注，彰显创新药行情正从BD驱动转向产品价值驱动，或预示行业新趋势。然而，在此背景下，却有两家创新药企逆势上扬。6月18日，亚盛医药股价盘中大涨近14%，最高触及71.8港元，再创历史新高；科济药业也在盘中涨幅超过9%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621150458a4b5df01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621150458a4b5df01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK1587","02171","BK1161","BK1574","06855","06978","BK1585"],"gpt_icon":1},{"id":"2544178588","title":"亚盛医药上涨5.32%，报37.79美元/股，总市值32.92亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2544178588","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544178588?lang=zh_cn&edition=fundamental","pubTime":"2025-06-20 21:39","pubTimestamp":1750426778,"startTime":"0","endTime":"0","summary":"6月20日，亚盛医药盘中上涨5.32%，截至21:39，报37.79美元/股，成交31.12万美元，总市值32.92亿美元。财务数据显示，截至2024年12月31日，亚盛医药收入总额9.81亿人民币，同比增长341.77%；归母净利润-4.05亿人民币，同比增长56.2%。目前,耐立克已被成功纳入《国家基本医疗保险、工伤保险和生育保险药品目录》。截至目前,公司共有4个在研新药获得16项FDA和1项欧盟孤儿药资格认定,2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506202146159524d41e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506202146159524d41e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2544178713","title":"亚盛医药点评：多项临床亮相ASCO和EHA大会，优秀数据助力管线商业化【东吴医药朱国广团队】","url":"https://stock-news.laohu8.com/highlight/detail?id=2544178713","media":"国广有话说","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544178713?lang=zh_cn&edition=fundamental","pubTime":"2025-06-20 21:26","pubTimestamp":1750425992,"startTime":"0","endTime":"0","summary":"而在此之前的5月30日，亚盛医药连续第八年两项ASCO年会，并带来了APG-2575联合疗法在初治或既往接受过维奈克拉治疗的髓系恶性肿瘤患者中的最新进展，优秀的数据为力胜克拉的未来出海前景增加确定性。本次大会上的多项临床都体现了奥雷巴替尼未来扩展适应症范围的潜力。本公司不会因接收人收到本报告而视其为客户。本公司将保留向其追究法律责任的权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250620215028a4b4c63b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250620215028a4b4c63b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1515","AAPG","06855","BK1574","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":4,"totalSize":172,"code":"91000000","status":"200"}]}}